Within-host viral dynamics of dengue serotype 1 infection

Journal of the Royal Society Interface

Volumn 11, Issue 96, 2014, Pages

  Clapham, Hannah E ^a,g   Tricou, Vianney ^b   Van Vinh Chau, Nguyen ^c   Simmons, Cameron P ^d,e,f   Ferguson, Neil M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INSTITUT PASTEUR DE BANGUI   (Central African Republic)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Dengue; Virus dynamics; Within host modelling

Indexed keywords

DYNAMICS; VIRUSES;

ANTI-VIRAL DRUGS; ANTIBODY-DEPENDENT ENHANCEMENTS; ANTIVIRAL THERAPY; DENGUE; POTENTIAL IMPACTS; VIRAL INFECTIONS; VIRAL PATHOGENESIS; VIRUS DYNAMICS;

IMMUNE SYSTEM;

ANTIVIRUS AGENT;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT ENHANCEMENT; ANTIVIRAL THERAPY; ARTICLE; DENGUE; DENGUE VIRUS 1; HEMORRHAGIC FEVER; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; PATHOGENESIS; SECONDARY INFECTION; SEROTYPE; TARGET CELL; VIET NAM; VIRAL CLEARANCE; VIREMIA; VIRUS ENTRY; VIRUS LOAD; VIRUS REPLICATION;

EID: 84901408429     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2014.0094     Document Type: Article

References (51)

1. Bhatt S et al. 2013 The global distribution and burden of dengue. Nature 496, 504-507. (doi:10.1038/nature12060)
2. Deen JL et al. 2006 The WHO dengue classification and case definitions: time for a reassessment. Lancet 368, 170-173. (doi:10.1016/S0140-6736(06)69006- 5)
3. Sabin AB. 1952 Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1, 30-50.
4. Nishiura H. 2008 Duration of short-lived cross-protective immunity against a clinical attack of dengue: a preliminary estimate. Dengue Bull. 32, 55-66.
5. Fischer DB, Halstead SB. 1970 Observations related to pathogenesis of dengue hemorrhagic fever. 5. Examination of age specific sequential infection rates using a mathematical model. Yale J. Biol. Med. 42, 329.
6. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. 1989 Antibody-dependent enhancement of dengue virus growth in human-monocytes as a risk factor for dengue hemorrhagic-fever. Am. J. Trop. Med. Hyg. 40, 444-451. (Pubitemid 19117544)
7. Morens DM. 1994 Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin. Infect. Dis. 19, 500-512. (doi:10.1093/clinids/19.3.500)
8. Valdes L, Guzman MG, Kouri G, Delgado J, Carbonell I, Cabrera MV, Rosario D, Vazquez S. 1999 Epidemiology of dengue and hemorrhagic dengue in Santiago, Cuba 1997. Rev. Panam. Salud Publica. 6, 16-25. (doi:10.1590/S1020- 49891999000600003)
9. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, Rothman AL, Libraty DH. 2004 Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 189, 990-1000. (doi:10.1086/382280)
10. Burke DS, Kliks S. 2006 Antibody-dependent enhancement in dengue virus infections. J. Infect. Dis. 193, 601-603. (doi:10.1086/499282)
11. Libraty DH et al. 2009 A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 6, 11. (doi:10.1371/journal.pmed.1000171)
12. Dejnirattisai W et al. 2010 Cross-reacting antibodies enhance dengue virus infection in humans. Science 328, 745-748. (doi:10.1126/science.1185181)
13. Mongkolsapaya J et al. 2003 Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9, 921-927. (doi:10.1038/nm887)
14. Mongkolsapaya J et al. 2006 T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J. Immunol. 176, 3821-3829. (doi:10.4049/jimmunol.176.6.3821)
15. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Rothman AL, Ennis FA, Nisalak A. 1997 Dengue in the early febrile phase: viremia and antibody responses. J. Infect. Dis. 176, 322-330. (doi:10.1086/514048)
16. Vaughn DW et al. 2000 Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181, 2-9. (doi:10.1086/315215)
17. Murgue B, Roche C, Chungue E, Deparis X. 2000 Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J. Med. Virol. 60, 432-438. (Pubitemid 30127315)
18. Duyen HTL et al. 2011 Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status. J. Infect. Dis. 203, 1292-1300. (doi:10.1093/infdis/jir014)
19. Yeh WT, Chen RF, Wang L, Liu JW, Shaio MF, Yang KD. 2006 Implications of previous subclinical dengue infection but not virus load in dengue hemorrhagic fever. FEMS Immunol. Med. Microbiol. 48, 84-90. (doi:10.1111/j.1574-695X.2006. 00127.x)
20. Beltramello M et al. 2010 The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8, 271-283. (doi:10.1016/j.chom.2010.08. 007)
21. Mathew A et al. 2011 B-cell responses during primary and secondary dengue virus infections in humans. J. Infect. Dis. 204, 1514-1522. (doi:10.1093/infdis/jir607)
22. Halstead SB, Orourke EJ. 1977 Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med. 146, 201-217. (doi:10.1084/jem.146.1.201)
23. Libraty DH, Pichyangkul S, Ajariyakhajorn C, Endy TP, Ennis FA. 2001 Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J. Virol. 75, 3501-3508. (doi:10.1128/JVI.75.8.3501-3508.2001)
24. Kou Z, Quinn M, Chen HY, Rodrigo W, Rose RC, Schlesinger JJ, Jin X. 2008 Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J. Med. Virol. 80, 134-146. (doi:10.1002/jmv.21051)
25. Simmons CP et al. 2012 Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials. PLoS Negl. Trop. Dis. 6, e1752. (doi:10.1371/journal.pntd.0001752)
26. Walker T et al. 2011 The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations. Nature 476, 450-453. (doi:10.1038/nature10355)
27. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995 Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126. (doi:10.1038/373123a0)
28. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996 HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-1586. (doi:10.1126/science.271.5255.1582)
29. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. 2006 Kinetics of influenza A virus infection in humans. J. Virol. 80, 7590-7599. (doi:10.1128/JVI.01623-05)
30. Lee HY et al. 2009 Simulation and prediction of the adaptive immune response to influenza A virus infection. J. Virol. 83, 7151-7165. (doi:10.1128/JVI.00098-09)
31. Handel A, Longini IM, Antia R. 2010 Towards a quantitative understanding of the within-host dynamics of influenza A infections. J. R. Soc. Interface 7, 35-47. (doi:10.1098/rsif.2009.0067)
32. Miao HY, Hollenbaugh JA, Zand MS, Holden-Wiltse J, Mosmann TR, Perelson AS, Wu H, Topham DJ. 2010 Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A Virus. J. Virol. 84, 6687-6698. (doi:10.1128/JVI.00266-10)
33. Saenz RA et al. 2010 Dynamics of influenza virus infection and pathology. J. Virol. 84, 3974-3983. (doi:10.1128/JVI.02078-09)
34. Smith AM, Ribeiro RM. 2010 Modeling the viral dynamics of influenza A virus infection. Crit. Rev. Immunol. 30, 291-298. (doi:10.1615/CritRevImmunol. v30.i3.60)
35. Heffernan JM, Keeling MJ. 2008 An in-host model of acute infection: measles as a case study. Theor. Popul. Biol. 73, 134-147. (doi:10.1016/j.tpb. 2007.10.003)
36. Zhou H, Deem MW. 2006 Sculpting the immunological response to dengue fever by polytopic vaccination. Vaccine 24, 2451-2459. (doi:10.1016/j.vaccine. 2005.12.031)
37. Nuraini N, Tasman H, Soewono E, Sidarto KA. 2009 A with-in host dengue infection model with immune response. Math. Comput. Model. 49, 1148-1155. (doi:10.1016/j.mcm.2008.06.016)
38. Gujarati TP, Ambika G. 2013 Virus antibody dynamics in primary and secondary dengue infections. J. Math. Biol. (doi:10.1007/s00285-013-0749-4)
39. Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B, Tran HT, Simmons CP. 2010 A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl. Trop. Dis. 4, e785. (doi:10.1371/ journal.pntd.0000785)
40. Tricou V, Minh NN, Farrar J, Tran HT, Simmons CP. 2011 Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue. PLoS Negl. Trop. Dis. 5, e1309. (doi:10.1371/journal.pntd. 0001309)
41. Nowak MA, May RM. 2000 Virus dynamics: mathematical principles of immunology and virology. Oxford, UK: Oxford University Press.
42. Gonzalez-Mejia ME, Doseff AI. 2009 Regulation of monocytes and macrophages cell fate. Front. Biosci. 14, 2413-2431. (doi:10.2741/3387)
43. iGPnotebook. White cell count. http://www.gpnotebook.co.uk (accessed 10 October 2013).
44. Cologna R, Rico-Hesse R. 2003 American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J. Virol. 77, 3929-3938. (doi:10.1128/JVI.77.7.3929-3938.2003)
45. Siler J, Hall M, Hitchens A. 1926 Dengue: its history, epidemiology, mechanism of transmission, etiology, clinical manifestations, immunity, and prevention. Monograph of the Philippine Bureau of Science. No. 20. Manila, Philippines: Bureau of printing.
46. Nishiura H, Halstead SB. 2007 Natural history of dengue virus (DENV)-1 and DENV-4 infections: reanalysis of classic studies. J. Infect. Dis. 195, 1007-1013. (doi:10.1086/511825)
47. Gilks WR, Richardson S, Spiegelhalter DJ. 2000 Markov chain Monte Carlo in practice. Boca Raton, FL: Chapman and Hall/CRC.
48. R Development Core Team. 2012 R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
49. Howey R, Quan M, Savill NJ, Matthews L, Alexandersen S, Woolhouse M. 2009 Effect of the initial dose of foot-and-mouth disease virus on the early viral dynamics within pigs. J. R. Soc. Interface 6, 835-847. (doi:10.1098/rsif.2008. 0434)
50. Ty Hang VT et al. 2010 Emergence of the Asian 1 genotype of dengue virus serotype 2 in Viet Nam: in vivo fitness advantage and lineage replacement in south-east Asia. PLoS Negl. Trop. Dis. 4, e757. (doi:10.1371/journal.pntd. 0000757)
51. Lloyd AL. 2001 The dependence of viral parameter estimates on the assumed viral life cycle: limitations of studies of viral load data. Proc. R. Soc. Lond. B 268, 847-854. (doi:10.1098/rspb.2000.1572)